1
|
Duker EO, Obodai E, Addo SO, Kwasah L, Mensah ES, Gberbi E, Anane A, Attiku KO, Boakye J, Agbotse GD, Dickson AE, Quarcoo JA, Darko PA, Larbi YA, Ntim NAA, Dzudzor B, Odoom JK. First Molecular Detection of SARS-CoV-2 in Sewage and Wastewater in Ghana. BIOMED RESEARCH INTERNATIONAL 2024; 2024:9975781. [PMID: 38595329 PMCID: PMC11003379 DOI: 10.1155/2024/9975781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 01/26/2024] [Accepted: 02/28/2024] [Indexed: 04/11/2024]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is shed in the stool of infected individuals and can be detected in sewage and wastewater contaminated with infected stool. This study is aimed at detecting the virus and its potential survival in sewage and wastewater in Ghana. The cross-sectional study included samples from 16 validated environmental surveillance sites in 7 regions of Ghana. A total of 354 samples composed of wastewater (280) and sewage (74) were collected from November 2020 to November 2022. Overall, 17% of the samples were positive for SARS-CoV-2 by real-time PCR, with 6% in sewage and 11% in wastewater. The highest number of positive samples was collected from the Greater Accra Region (7.3%) with the least recorded in the Bono East Region (0.6%). Further characterization of the positive samples using the next-generation sequencing (NGS) approach yielded two variants: Alpha (B.1.1.7) and Delta (AY.36). Attempts to isolate SARS-CoV-2 in the Vero cell line were not successful probably due to the low viral load concentrations (Ct values > 35) or prolonged exposure to high temperatures rendering the virus noninfectious. Our findings suggest that SARS-CoV-2 RNA in sewage and wastewater may not be infectious, but the prevalence shows that the virus persists in the communities within Ghana.
Collapse
Affiliation(s)
- Ewurabena Oduma Duker
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Evangeline Obodai
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Seth Offei Addo
- Parasitology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Lorreta Kwasah
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Edna Serwah Mensah
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Emmanuel Gberbi
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Abraham Anane
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Keren O. Attiku
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Jessica Boakye
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Gayheart Deladem Agbotse
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Angelina Evelyn Dickson
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Joseph Ahia Quarcoo
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Patience Akosua Darko
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Yaw Awuku Larbi
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Nana Afia Asante Ntim
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| | - Bartholomew Dzudzor
- Department of Medical Biochemistry, University of Ghana Medical School, University of Ghana, Legon, Accra, Ghana
| | - John Kofi Odoom
- Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana
| |
Collapse
|
2
|
Hamisu AW, Etapelong SG, Ayodeji I, Richard B, Fiona B, Gidado S, Abbott SL, Edukugho AA, Bolu O, Adeyelu A, Mawashi KY, Adamu US, Nsubuga P, Shuaib F. Experience and findings from surveillance peer review in Nigeria, August 2017-May 2019. Pan Afr Med J 2023; 45:9. [PMID: 38370096 PMCID: PMC10874099 DOI: 10.11604/pamj.supp.2023.45.2.39450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Accepted: 08/23/2023] [Indexed: 02/20/2024] Open
Abstract
Introduction acute flaccid paralysis (AFP) surveillance is the gold standard of the Global Polio Eradication Initiative (GPEI) for detecting cases of poliomyelitis and tracking poliovirus transmission. Nigeria's AFP surveillance performance indicators are among the highest in countries of the World Health Organization (WHO) African Region. The primary AFP surveillance performance indicators are the rate of non-polio AFP among children and the proportion of timely, adequate specimen collection. The surveillance working group of the National Emergency Operations Centre assessed the quality of AFP surveillance data in some reportedly high-performing states. Methods we conducted a retrospective review of AFP surveillance performance indicators in Nigeria for 2010-2019. We also reviewed data in reports from four groups of surveillance peer reviews and validation visits (conducted by in-country GPEI partners) during August 2017-May 2019 in 16 states with high primary AFP surveillance indicators; the validation visits reviewed clinical information and the dates of specimen collection and onset of paralysis with caretakers. Results there were consistently increasing AFP surveillance primary performance indicators during 2010-2016, followed by declines during 2017-2019. From the data for 16 states with peer reviews conducted from August 2017-May 2019, overall concordance of reported and "true" (validated) AFP indicator data in peer review investigations was highly variable. True AFP concordance ranged from 58%-100%, and stool timeliness concordance ranged from 56%-95%. The most common clinical causes of reported AFP cases that were not true AFP were spastic paralysis, malaria, sickle cell disease, and malnutrition. All the states that participated in peer reviews developed surveillance improvement plans based on the gaps identified. Conclusion Nigeria has highly sensitive AFP surveillance according to reported primary AFP performance indicators. The findings of peer reviews indicate that the AFP surveillance system needs to be strengthened and well-supervised to enhance data quality.
Collapse
Affiliation(s)
| | | | - Isiaka Ayodeji
- World Health Organization, Nigeria Country Office, Abuja, Nigeria
| | - Banda Richard
- World Health Organization, Nigeria Country Office, Abuja, Nigeria
| | - Braka Fiona
- World Health Organization, Nigeria Country Office, Abuja, Nigeria
| | - Saheed Gidado
- National Stop Transmission of Polio (NSTOP)/African Field Epidemiology Network (AFENET), Aso, Federal Capital Territory, Abuja, Nigeria
| | - Samuel Luka Abbott
- National Stop Transmission of Polio (NSTOP)/African Field Epidemiology Network (AFENET), Aso, Federal Capital Territory, Abuja, Nigeria
| | - Aboyowa Arayuwa Edukugho
- National Stop Transmission of Polio (NSTOP)/African Field Epidemiology Network (AFENET), Aso, Federal Capital Territory, Abuja, Nigeria
| | - Omotayo Bolu
- Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | - Asekun Adeyelu
- Centers for Disease Control and Prevention, Atlanta, Georgia, United States
| | | | - Usman Said Adamu
- National Primary Healthcare Development Authority, Abuja, Nigeria
| | - Peter Nsubuga
- Global Public Health Solutions, Atlanta, Georgia, United States
| | - Faisal Shuaib
- National Primary Healthcare Development Authority, Abuja, Nigeria
| |
Collapse
|
3
|
Rodríguez R, Juárez E, Estívariz CF, Cajas C, Rey-Benito G, Amézquita MOB, Miles SJ, Orantes O, Freire MC, Chévez AE, Signor LC, Sayyad L, Jarquin C, Cain E, Villalobos Rodríguez AP, Mendoza L, Ovando CA, Mayorga HDJB, Gaitán E, Paredes A, Belgasmi-Allen H, Gobern L, Rondy M. Response to Vaccine-Derived Polioviruses Detected through Environmental Surveillance, Guatemala, 2019. Emerg Infect Dis 2023; 29:1524-1530. [PMID: 37486156 PMCID: PMC10370855 DOI: 10.3201/eid2908.230236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/25/2023] Open
Abstract
Guatemala implemented wastewater-based poliovirus surveillance in 2018, and three genetically unrelated vaccine-derived polioviruses (VDPVs) were detected in 2019. The Ministry of Health (MoH) response included event investigation through institutional and community retrospective case searches for acute flaccid paralysis (AFP) during 2018-2020 and a bivalent oral polio/measles, mumps, and rubella vaccination campaign in September 2019. This response was reviewed by an international expert team in July 2021. During the campaign, 93% of children 6 months <7 years of age received a polio-containing vaccine dose. No AFP cases were detected in the community search; institutional retrospective searches found 37% of unreported AFP cases in 2018‒2020. No additional VDPV was isolated from wastewater. No evidence of circulating VDPV was found; the 3 isolated VDPVs were classified as ambiguous VDPVs by the international team of experts. These detections highlight risk for poliomyelitis reemergence in countries with low polio vaccine coverage.
Collapse
|
4
|
Adesola RO, Idris I, Opuni E. Public health concerns surrounding the cVDPV2 outbreak in Africa: Strategies for prevention and control with a special focus on Nigeria. Health Sci Rep 2023; 6:e1269. [PMID: 37187504 PMCID: PMC10176430 DOI: 10.1002/hsr2.1269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Revised: 03/25/2023] [Accepted: 03/30/2023] [Indexed: 05/17/2023] Open
Abstract
Background and Aim Poliovirus is a global health issue that affects children in different parts of the world. Despite the efforts of national, international, and nongovernmental organizations to eradicate the disease, it is re-emerging in Africa due to poor sanitation, vaccine hesitancy, new ways of transmission, and poor surveillance among others. Circulating vaccine-derived poliovirus type 2 (cVDPV2) is a major step in eradicating poliovirus and preventing outbreaks in developing countries. Strengthening African healthcare systems, increasing surveillance, hygiene and sanitation, and proper mass vaccination to achieve herd immunity are required in the fight against polio disease. This paper discusses the outbreak of cVDPV2, public health challenges, and recommendations in Africa with a special emphasis on Nigeria. Methods We searched for articles documenting the incidence of cVDPV2 in Nigeria and other African countries on Pubmed, Google Scholar, and Scopus. Results A total of 68 distinct cVDPV2 genetic emergences were found across 34 nations between April 2016 to December 2020, and in Nigeria, three cVDPV2 emergences were found. Also, 1596 instances of acute flaccid paralysis linked to cVDPV2 outbreaks were reported in four areas of the World Health Organization where Africa contributed 962 cases out of 1596 cases. Available data indicate that Africa has the most cVDPV2 cases and is associated with various challenges like the unidentified virus source, poor sanitation system, and inability to achieve herd immunity of the cVDPV2 vaccine. Conclusion Collaborative efforts of stakeholders are crucial in combating infectious diseases, especially those transmitted via environments such as water and air, like poliovirus. Therefore, a collaboration between environmental health workers, veterinarians, community health workers, laboratory scientists, policymakers, and other professionals is required.
Collapse
Affiliation(s)
- Ridwan O. Adesola
- Department of Veterinary Medicine, Faculty of Veterinary MedicineUniversity of IbadanIbadanNigeria
| | - Ibrahim Idris
- Department of Veterinary Medicine, Faculty of Veterinary MedicineUsmanu Danfodiyo UniversitySokotoNigeria
| | - Emmanuel Opuni
- Department of Health PolicyThe London School of Economics and Political ScienceLondonUK
| |
Collapse
|
5
|
Tushabe P, Bwogi J, Eliku JP, Aine F, Birungi M, Gaizi J, Nakabazzi L, Kabaliisa T, Turyahabwe I, Namuwulya P, Nanteza MB, Bukenya H, Kanyesigye C, Katushabe E, Ampeire I, Kisakye A, Bakamutumaho B, Byabamazima CR. Environmental surveillance detects circulating vaccine-derived poliovirus type 2 that was undetected by acute flaccid paralysis surveillance in 2021 in Uganda. Arch Virol 2023; 168:140. [PMID: 37059887 PMCID: PMC10104764 DOI: 10.1007/s00705-023-05759-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Accepted: 03/14/2023] [Indexed: 04/16/2023]
Abstract
The success of the global polio eradication initiative is threatened by the genetic instability of the oral polio vaccine, which can result in the emergence of pathogenic vaccine-derived polioviruses following prolonged replication in the guts of individuals with primary immune deficiencies or in communities with low vaccination coverage. Through environmental surveillance, circulating vaccine-derived poliovirus type 2 was detected in Uganda in the absence of detection by acute flaccid paralysis (AFP) surveillance. This underscores the sensitivity of environmental surveillance and emphasizes its usefulness in supplementing AFP surveillance for poliovirus infections in the race towards global polio eradication.
Collapse
Affiliation(s)
- Phionah Tushabe
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda.
| | - Josephine Bwogi
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - James Peter Eliku
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Francis Aine
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Molly Birungi
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Joseph Gaizi
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Lucy Nakabazzi
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Theopista Kabaliisa
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Irene Turyahabwe
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Prossy Namuwulya
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Mary Bridget Nanteza
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Henry Bukenya
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | | | - Edson Katushabe
- World Health Organization, Uganda Country Office, Kampala, Uganda
| | | | - Annet Kisakye
- World Health Organization, Uganda Country Office, Kampala, Uganda
| | - Barnabas Bakamutumaho
- Expanded Programme on Immunization Laboratory, Uganda Virus Research Institute, Entebbe, Uganda
| | - Charles R Byabamazima
- WHO Inter-Country Support Team Office for Eastern and Southern Africa (IST/ESA), Harare, Zimbabwe
| |
Collapse
|
6
|
Yu-Ping Z, Jing L, Teng H, Zhi-Fang Y, Ting Z, Yan-Chun C, Zhi-Mei Z, Yu-Ting F, Jun-Hui T, Qing-Hai Y, Ding-Kai W, Guo-Liang L, Xiao-Lei Y, Li Y, Hong-Bo C, Jian-Feng W, Rui-Ju J, Lei Y, Wei C, Wei Y, Ming-Xue X, Qiong-Zhou Y, Jing P, Li S, Chao H, Yan D, Lu-Kui C, Jian Z, Yu W, Hong-Sen L, Wei H, Zhao-Jun M, Chang-Gui L, Qi-Han L, Jing-Si Y. Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination. NPJ Vaccines 2023; 8:44. [PMID: 36934085 PMCID: PMC10024706 DOI: 10.1038/s41541-023-00642-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 03/07/2023] [Indexed: 03/20/2023] Open
Abstract
To provide a basis for further optimization of the polio sequential immunization schedule, this study evaluated the effectiveness of booster immunization with one dose of bivalent oral poliovirus vaccine (bOPV) at 48 months of age after different primary polio immunization schedules. At 48 months of age, one dose of bOPV was administered, and their poliovirus types 1-3 (PV1, PV2, and PV3, respectively)-specific neutralizing antibody levels were determined. Participants found to be negative for any type of PV-specific neutralizing antibody at 24, 36, or 48 months of age were re-vaccinated with inactivated polio vaccine (IPV). The 439 subjects who received a bOPV booster immunization at the age of 48 months had lower PV2-specific antibody levels compared with those who received IPV. One dose of IPV during basic polio immunization induced the lowest PV2-specific antibody levels. On the basis of our findings, to ensure that no less than 70% of the vaccinated have protection efficiency, we recommend the following: if basic immunization was conducted with 1IPV + 2bOPV (especially Sabin strain-based IPV), a booster immunization with IPV is recommended at 36 months of age, whereas if basic immunization was conducted with 2IPV + 1bOPV, a booster immunization with IPV is recommended at 48 months of age. A sequential immunization schedule of 2IPV + 1bOPV + 1IPV can not only maintain high levels of antibody against PV1 and PV3 but also increases immunity to PV2 and induces early intestinal mucosal immunity, with relatively good safety. Thus, this may be the best sequential immunization schedule for polio in countries or regions at high risk for polio.
Collapse
Affiliation(s)
- Zhao Yu-Ping
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Li Jing
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Huang Teng
- GuangXi Province Center for Disease Prevention and Control, Nanning, China
| | - Ying Zhi-Fang
- National Institutes for Food and Drug Control, Beijing, China
| | - Zhao Ting
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Che Yan-Chun
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Zhao Zhi-Mei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Fu Yu-Ting
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Tao Jun-Hui
- Liujiang District Center for Disease Prevention and Control, Liuzhou, China
| | - Yang Qing-Hai
- Liucheng County Center for Disease Prevention and Control, Liuzhou, China
| | - Wei Ding-Kai
- Rong'an County Center for Disease Prevention and Control, Liuzhou, China
| | - Li Guo-Liang
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Yang Xiao-Lei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Yi Li
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Chen Hong-Bo
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Wang Jian-Feng
- National Institutes for Food and Drug Control, Beijing, China
| | - Jiang Rui-Ju
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Yu Lei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Cai Wei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Yang Wei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Xie Ming-Xue
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Yin Qiong-Zhou
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Pu Jing
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Shi Li
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Hong Chao
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Deng Yan
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Cai Lu-Kui
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Zhou Jian
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
| | - Wen Yu
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
| | - Li Hong-Sen
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Huang Wei
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China
| | - Mo Zhao-Jun
- GuangXi Province Center for Disease Prevention and Control, Nanning, China.
| | - Li Chang-Gui
- National Institutes for Food and Drug Control, Beijing, China.
| | - Li Qi-Han
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China.
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China.
| | - Yang Jing-Si
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China.
- National Local Joint Engineering Research Center for Biological Products of Viral Infectious Diseases, Kunming, China.
- Kunming Science and Technology Innovation Centre for Research, Development and Industrialization of New Outbreaks and Emerging Highly Pathogenic Pathogens Vaccines, Kunming, China.
| |
Collapse
|
7
|
Environmental Monitoring for Enteroviruses in Maputo, Mozambique—2018. Pathogens 2022; 11:pathogens11050527. [PMID: 35631048 PMCID: PMC9147478 DOI: 10.3390/pathogens11050527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 04/22/2022] [Accepted: 04/27/2022] [Indexed: 12/04/2022] Open
Abstract
Due to the possibility of wild poliovirus importation from endemic regions and the high circulation of vaccine-derived poliovirus type 2 in the African region, Mozambique implemented a surveillance program to monitor the circulation of enteroviruses in the environment. From January to November 2018, a period that immediately preceded the cVDPV outbreak in Africa, 63 wastewater samples were collected from different areas in Maputo city. A total of 25 samples (39.7%) were positive based on cell culture isolation. Non-polio enteroviruses were found in 24 samples (24/25; 96%), whereas 1 Sabin-related poliovirus was isolated. Neither wild nor vaccine-derived poliovirus was detected. High circulation of EVB species was detected. Environmental surveillance in the One Health approach, if effectively applied as support to acute flaccid paralysis, can be a powerful aid to the public health system to monitor poliovirus besides non-polio enteroviruses in polio-free areas.
Collapse
|